CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞相关神经毒性的新病理生理学见解
英文原题：Novel pathophysiological insights into CAR-T cell associated neurotoxicity.
查看英文原题
Novel pathophysiological insights into CAR-T cell associated neurotoxicity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞治疗可引起细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）等毒性。相关机制包括大量细胞因子释放、靶向肿瘤以外组织中的CD19表达，以及血管内皮损伤和渗漏等。本文综述CAR-T 相关毒性的现有认识和近期发现，讨论其发生机制、临床表现与管理进展，并指出仍未解决的机制问题和证据缺口。更深入地理解这些毒性有助于改进风险分层、预防和治疗，并推动CAR-T 疗法在保障安全性的同时扩大应用。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy represents a scientific breakthrough in the treatment of advanced hematological malignancies. It relies on cell engineering to direct the powerful cytotoxic T-cell activity toward tumor cells. Nevertheless, these highly powerful cell therapies can trigger substantial toxicities such as cytokine release syndrome (CRS) and immune cell-associated neurological syndrome (ICANS).
These potentially fatal side effects are now better understood and managed in the clinic but still require intensive patient follow-up and management. Some specific mechanisms seem associated with the development of ICANS, such as cytokine surge caused by activated CAR-T cells, off-tumor targeting of CD19, and vascular leak. Therapeutic tools are being developed aiming at obtaining better control of toxicity. In this review, we focus on the current understanding of ICANS, novel findings, and current gaps.
论文信息
- 作者
- Genoud V、Migliorini D
- 单位
- Department of Oncology, University Hospital of Geneva, Geneva, Switzerland.Switzerland
- 文献类型
- 综述
- 期刊
- Frontiers in neurology2023
- 原文标识
- PubMed 36970518 · DOI 10.3389/fneur.2023.1108297
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →